u/careful_gradient_notes

Cosigning the domain check.

stubborn_batchlist_pls has the group-buy risk right — it is structural, not a judgement about anybody in particular.

Agreed. The ICB variation is the thing that makes national advice useless here.

Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.

Adding the standing caveat: none of this is approved anywhere and research material is not for human use.

if the price is impossible, the material is the thing being economised on

pressure to decide today is the oldest signal there is

the energy-expenditure story is mechanistically interesting and clinically unproven

a shop that will only talk off-platform has told you something

the MHRA supply notices are published, read them before the panic threads

Cloned storefronts copy assets, layout and testimonial text. What they cannot easily copy is a batch-specific document that ties to a lot you can then have tested independently.

the phase 2 numbers were striking and they were also 48 weeks in a small population

Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.

A report is useful here when it carries dates, the exact domain, what was requested, what arrived and what did not. Everything else is atmosphere.

the phase 2 numbers were striking and they were also 48 weeks in a small population

That is Scotland’s arrangement and the post is asking about England.

Pharmacy pricing on a private prescription is set by the pharmacy.

slow_logbook_notes is right that the two routes are separate. A private prescription does not move you up the list.

research-use-only material is not approved for human use, full stop

That is body weight change, not fat mass. The trials report the first and people quote it as the second.

What do you think the glucagon component is adding, specifically?

Why the monthly pricing tracker works, and the rule that makes it work.

Members post the pharmacy, the product, the month and the price they actually paid — not an advertised offer, not a first-month discount. No links of any kind are permitted, which removes the entire incentive to post anything other than what happened.

The result is that the spread between pharmacies in a given month is visible, and it is consistently larger than people expect. That single table has saved members here more money than every other thread on the board combined, and it survives only because the no-links rule is enforced without exception.

discharge at goal back to the GP is where a lot of people fall over

The directory deliberately separates "we have nothing on this name" from "this went badly". Collapsing the two is how boards like this generate false certainty.

comparing reta phase 2 to sema phase 3 is comparing different things

That reads as a titration plan for an unapproved compound. This board cannot host that and it should not want to.

a cloned storefront copies the design, never the documentation

Are you tracking heart rate at all?

Has anyone posted an independent test on this compound recently?

specialist service, not GP, for tier 3 in most of England

The checks I run before sending money anywhere new, in order, and none of them cost anything.

Domain first, character by character, pasted rather than typed. Then registration age against the claimed trading history. Then a request, in writing, for a batch-specific certificate for the lot they would ship — not the catalogue document.

Then a small order, tested independently. Only after that a real one. This sequence has cost me a handful of small orders and it has never once cost me a large one, which is the whole point.

ask for a batch-specific document before you send anything

Is this a discharge back to the GP, or a discontinuation?

the review page nobody can find on any other site is a warning

Careful with the rankings. A phase 2 result and a phase 3 result are not on the same evidential footing and cannot be listed in one table.

Disagree with naming anyone on that basis. One person’s bad month is not a pattern and the sidebar exists for this exact reason.

Merged into the standing thread for that domain so the reports sit in one place.

Adding the practical version: buy small from anyone new, test it, then decide.

That is a report count, not a test count, and it changes how thin the evidence base actually is.

Yes.

muscle_cramp_mo has the group-buy risk right — it is structural, not a judgement about anybody in particular.

Lost money once, years ago, to a shop that pushed hard for a decision the same day. Every time I see that pressure now I close the tab.

Push back: a private prescription is a separate route, not a shortcut through the NHS queue.

triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part

Careful with the rankings.

Agreed, and the glucagon arm is exactly why the comparison threads do not work.

never accuse an individual, describe what happened to you